Q-omics provides the consensus-scored ZNF772 profile across patient tissues and cancer cell-line models. ZNF772 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF772 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZNF772 RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where ZNF772 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF772 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF772 survival associations across molecular data types. ZNF772 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF772 RNA expression–survival associations across cancer types. High ZNF772 expression shows unfavorable associations in SKCM, LGG and ACC, but favorable associations in KIRC, SCLC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF772 RNA expression.
This table summarizes ZNF772 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF772. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF772 shows lower tumor expression in KIRC, COAD, KICH and THCA and higher tumor expression in BLCA and LIHC. The KIRC box plot shows higher ZNF772 RNA expression in normal versus tumor tissue (log2 FC = −0.870, t-test p < 0.001).
This table shows molecular features associated with ZNF772 in patient tissues and cancer cell lines. In patient samples, ZNF772 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF772 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
